Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the future holds and how market participants will react to the bountiful news that floods in each day. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 (including dividend payments). Conversely, hedge funds’ 30 preferred S&P 500 stocks (as of June 2018) generated a return of 15.1% during the same 12-month period, with 53% of these stock picks outperforming the broader market benchmark. Coincidence? It might happen to be so, but it is unlikely. Our research covering the last 18 years indicates that hedge funds’ stock picks generate superior risk-adjusted returns. That’s why we believe it isn’t a waste of time to check out hedge fund sentiment before you invest in a stock like Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) investors should be aware of a decrease in activity from the world’s largest hedge funds of late. ALNY was in 32 hedge funds’ portfolios at the end of September. There were 35 hedge funds in our database with ALNY positions at the end of the previous quarter. Our calculations also showed that ALNY isn’t among the 30 most popular stocks among hedge funds.

In today’s marketplace there are many formulas stock market investors put to use to assess publicly traded companies. A pair of the most innovative formulas are hedge fund and insider trading signals. Our experts have shown that, historically, those who follow the best picks of the elite hedge fund managers can outpace the broader indices by a significant amount (see the details here).

Lee Ainslie MAVERICK CAPITAL

We’re going to analyze the recent hedge fund action encompassing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

How are hedge funds trading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)?

At the end of the third quarter, a total of 32 of the hedge funds tracked by Insider Monkey were long this stock, a change of -9% from the previous quarter. On the other hand, there were a total of 31 hedge funds with a bullish position in ALNY at the beginning of this year. So, let’s examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

ALNY_dec2018

The largest stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was held by Maverick Capital, which reported holding $132.3 million worth of stock at the end of September. It was followed by Perceptive Advisors with a $104.8 million position. Other investors bullish on the company included Point72 Asset Management, 12 West Capital Management, and Bridger Management.

Seeing as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has faced a decline in interest from the entirety of the hedge funds we track, logic holds that there is a sect of hedge funds who sold off their full holdings heading into Q3. It’s worth mentioning that Samuel Isaly’s OrbiMed Advisors said goodbye to the largest stake of the “upper crust” of funds monitored by Insider Monkey, comprising about $124.7 million in stock. Behzad Aghazadeh’s fund, venBio Select Advisor, also dumped its stock, about $69 million worth. These moves are interesting, as aggregate hedge fund interest dropped by 3 funds heading into Q3.

Let’s now review hedge fund activity in other stocks – not necessarily in the same industry as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) but similarly valued. These stocks are Lennox International Inc. (NYSE:LII), The Interpublic Group of Companies Inc (NYSE:IPG), Sun Communities Inc (NYSE:SUI), and East West Bancorp, Inc. (NASDAQ:EWBC). This group of stocks’ market valuations are closest to ALNY’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
LII 23 210602 5
IPG 16 774108 0
SUI 23 556542 3
EWBC 29 443982 5
Average 22.75 496309 3.25

View table here if you experience formatting issues.
As you can see these stocks had an average of 22.75 hedge funds with bullish positions and the average amount invested in these stocks was $496.31 billion. That figure was $728 million in ALNY’s case. East West Bancorp, Inc. (NASDAQ:EWBC) is the most popular stock in this table. On the other hand The Interpublic Group of Companies Inc (NYSE:IPG) is the least popular one with only 16 bullish hedge fund positions. Compared to these stocks Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...